Amanote Research
Register
Sign In
Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer
Cancer
- United States
doi 10.1002/cncr.31672
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
August 15, 2018
Authors
Unknown
Publisher
Wiley
Related search
The Efficiency of 18f-FDG PET-CT for Predicting the Major Pathologic Response to the Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
European Journal of Nuclear Medicine and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Sustained CA19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival
Oncologist
Cancer Research
Medicine
Oncology
Neoadjuvant Chemotherapy of Resectable Advanced Gastric Cancer
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Complete Pathological Response Following Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer - A Case Report and Review
BMC Cancer
Cancer Research
Oncology
Genetics
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine
Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer
British Journal of Surgery
Surgery
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results From a Multicenter Study (LCMC3)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Prognostic Evaluation of Patients With Resectable Lung Cancer Using Systemic Inflammatory Response Parameters
Oncology Letters
Cancer Research
Oncology
